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From the Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada.Figure 1 Surface electrocardiogram from the subcutaneous implantable cardioverter-deﬁbrillator demonstrating appropriate QRS-T complex discrimination
during implantation and normokalemia.Introduction
The implantable cardioverter-deﬁbrillator (ICD) has reduced
mortality in survivors of sudden cardiac arrest and patients at
high risk of sudden cardiac death.1 This beneﬁt comes at the
cost of device-related complications, including those related
to transvenous leads.2 The subcutaneous ICD (S-ICD) is an
alternative to the conventional transvenous ICD (TV-ICD)
system and has no transvenous leads, thereby avoiding
endocardial lead–related complications.2 However, with
only subcutaneous electrodes, rhythm detection and discrim-
ination is a much more challenging task for the S-ICD. We
describe a case of ventricular ﬁbrillation induced by inap-
propriate shocks from the S-ICD owing to T-wave over-
sensing (TWOS) in the setting of hyperkalemia and dialysis-
dependent chronic renal failure.Case report
A 33-year-old man with a history of dilated cardiomyopathy
with reduced left ventricular ejection fraction (25%) and end-
stage renal disease requiring intermittent hemodialysis was
resuscitated in the community after experiencing rapid
monomorphic ventricular tachycardia with syncope. HeKEYWORDS Deﬁbrillators; implantable; Subcutaneous ICD; ICD sensing;
Cardiac arrest; Ventricular arrhythmias
ABBREVIATIONS ICD ¼ implantable cardioverter-defibrillator; S-ICD ¼
subcutaneous implantable cardioverter-defibrillator; TV-ICD ¼
transvenous implantable cardioverter-defibrillator; TWOS ¼ T-wave
oversensing (Heart Rhythm Case Reports 2015;1:257–259)
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Medtronic, Minneapolis, MN) for secondary prevention
prior to hospital discharge. During the patient’s routine
assessments in the device clinic, intermittent TWOS was
noted, but in each instance it had been appropriately
discriminated by the TWOS algorithms of the device and
no inappropriate therapies had been delivered. In follow-up,
the patient developed a persistent coagulase-negative Staph-
ylococcus bacteremia, which ultimately required the removal
of the ICD system 13 months after the original implant.
The patient required a chronic indwelling catheter for
hemodialysis; therefore, to mitigate risk of future infection
following resolution of the patient’s bacteremia, the patient
received an S-ICD device implantation (SQ-RX Pulse
Generator Model 1010 and Q-TRAK Subcutaneous Elec-
trode Model 3010; Cameron Health/Boston Scientiﬁc, San
Clemente, CA). The generator was placed at the cardiac
apex/anterior axillary line and the subcutaneous electrode
along the right sternal border. There was good QRS-T
complex discrimination at implantation (Figure 1) and
deﬁbrillation threshold testing was successful with reverse
polarity at 80 joules.
Approximately 1 month after S-ICD placement, the
patient presented to hospital with complaints of multiple,
unprovoked device shocks. He reported missing 2 consec-
utive dialysis treatments and his serum potassium was found
to be elevated at 7.0 mmol/L. Interrogation of the S-ICD
revealed 5 episodes of tachycardia and 17 shocks delivered.
Rhythm analysis showed that each reported episode of
tachycardia was due to TWOS. During the ﬁrst 3 episodes,
between 3 and 5 inappropriate shocks were delivered during
sinus rhythm. During the fourth and ﬁfth episodes, the
inappropriate shocks were delivered on the T-wave andpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.04.007
Figure 2 Surface electrocardiogram from the subcutaneous implantable cardioverter-deﬁbrillator demonstrating inappropriate shocks due to T-wave
oversensing in the setting of hyperkalemia (serum potassium 7.0 mmol/L), leading to sustained ventricular ﬁbrillation requiring 4 shocks prior to termination.
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KEY TEACHING POINTS
 The most frequent complication of the
subcutaneous implantable cardioverter-
deﬁbrillator (S-ICD) is inappropriate shocks. In
contrast to transvenous ICDs, inappropriate shocks
from S-ICDs are often due to T-wave oversensing.
 T-wave oversensing by the S-ICD may occur in the
context of hyperkalemia.
 The population in which there may be a preference
for an S-ICD may also be at the greatest risk of the
limitations of rhythm detection and discrimination.
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and ventricular ﬁbrillation, respectively (Figure 2). The
ventricular ﬁbrillation lasted approximately 87 seconds and
required 4 shocks before the patient returned to normal sinus
rhythm. Urgent hemodialysis was initiated for correction of
hyperkalemia and no further shocks occurred. The condi-
tional shock zone and shock zone were increased to 200 and
230 beats per minute, respectively. Compliance with dialysis
was recommended and the patient was discharged with
clinical follow-up.
Discussion
The S-ICD system is a novel technology that offers a less
invasive alternative to the conventional TV-ICD system.2
Preference may be given to the S-ICD in patients for whom
there is a desire to avoid the complications associated with
intracardiac leads. These patients may include the young,
those with poor vascular access, and those at high risk of
bacteremia, such as patients with chronic indwelling endo-
vascular catheters or those receiving hemodialysis. However,
long-term safety data for the S-ICD are lacking in these
complex patients.
The most frequent complication of the S-ICD is inappro-
priate shocks.3,4 While inappropriate shocks from TV-ICDs
are most often due to supraventricular arrhythmias,inappropriate shocks from S-ICDs are most often due to
oversensing of T-waves and low-amplitude cardiac signals.2
Transient hyperkalemia is common in dialysis patients, a
population that is difﬁcult to manage and in which an S-ICD
might be more likely to be considered owing to a decreased
risk of infection. Unfortunately, hyperkalemia represents one
mechanism that may lead to TWOS in the S-ICD. Increased
extracellular potassium concentrations may decrease the
amplitude of the QRS complex and increase the amplitude
of the T-wave. Hyperkalemia may also increase deﬁbrillation
thresholds.5 In this case, the impaired ability of the S-ICD to
discriminate the QRS-T complex led to the induction of
ventricular ﬁbrillation after a shock was delivered on the T-
wave. The patient required 4 shocks at maximum device
outputs to terminate ventricular ﬁbrillation.Conclusion
The population in which there may be a preference for an S-
ICDmay also be the population most at risk of the limitations
of this technology. Further enhancement of the rhythm
detection/discrimination abilities of these devices will sig-
niﬁcantly enhance their clinical utility. Higher deﬁbrillation
safety margins at implantation may also be warranted. To our
knowledge, this is the ﬁrst report of TWOS in the setting of
hyperkalemia leading to inappropriate shocks from an S-
ICD, resulting in sustained ventricular ﬁbrillation.References
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